Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study.
Ontology highlight
ABSTRACT: INTRODUCTION:Severe pneumonia caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) remains a difficult-to-treat infection. Considering the poor lung penetration of most antibiotics, the choice of the better antibiotic regimen is debated. METHODS:We performed a prospective, observational, multicenter study conducted from January 2017 to June 2020. All consecutive hospitalized patients with severe pneumonia due to MDR-AB were included in the study. The primary endpoint of the study was to evaluate risk factors associated with survival or death at 30 days from pneumonia onset. A propensity score for receiving therapy with fosfomycin was added to the model. RESULTS:During the study period, 180 cases of hospital-acquired pneumonia, including ventilator-associated pneumonia, caused by MDR-AB strains were observed. Cox regression analysis of factors associated with 30-day mortality, after propensity score, showed that septic shock, and secondary bacteremia were associated with death, while a fosfomycin-containing regimen was associated with 30-day survival. Antibiotic combinations with fosfomycin in definitive therapy for 44 patients were: fosfomycin?+?colistin in 11 (25%) patients followed by fosfomycin?+?carbapenem?+?tigecycline in 8 (18.2%), fosfomycin?+?colistin?+?tigecycline in 7 (15.9%), fosfomycin?+?rifampin in 7 (15.9%), fosfomycin?+?tigecycline in 6 (13.6%), fosfomycin?+?carbapenem in 3 (6.8%), and fosfomycin?+?aminoglycoside in 2 (4.5%). CONCLUSIONS:This real-life clinical experience concerning the therapeutic approach to severe pneumonia caused by MDR-AB provides useful suggestions to clinicians, showing the use of different antibiotic regimens with a predominant role for fosfomycin. Further randomized clinical trials are necessary to confirm or exclude these observations.
SUBMITTER: Russo A
PROVIDER: S-EPMC7568458 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA